Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Puma Biotechnology Inc
PBYICurrent price
3.00 USD
-0.01 USD (-0.33%)
Last closed
3.03 USD
Company
www.pumabiotechnology.com
ISIN
US74587V1070
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
149 328 512 USD
Yield for 12 month
-40.24 %
1Y
3Y
5Y
10Y
15Y
PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. Address: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.33 USDP/E ratio
4.85Dividend Yield
–Current Year
+230 468 000 USD
Last Year
+235 637 000 USD
Current Quarter
+59 077 000 USD
Last Quarter
+80 542 000 USD
Current Year
+166 064 000 USD
Last Year
+172 955 000 USD
Current Quarter
+45 156 000 USD
Last Quarter
+51 445 000 USD
Key Figures PBYI
1 year
3 years
5 years
10 years
EBITDA
42 490 000 USD
Operating Margin TTM
Price to Earnings
4.85
Return On Assets TTM
8.72 %
PEG Ratio
0.030
Return On Equity TTM
41.60 %
Wall Street Target Price
4.33 USD
Revenue TTM
230 468 000 USD
Book Value
1.88 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-18.20 %
Dividend Yield
–
Gross Profit TTM
166 064 000 USD
Earnings per share
0.62 USD
Diluted Eps TTM
0.62 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
58.50 %
Profit Margin
13.14 %
Dividend Analytics PBYI
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PBYI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation PBYI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
4.85
Forward PE
7.00
Enterprise Value Revenue
0.53
Price Sales TTM
0.65
Enterprise Value EBITDA
2.55
Price Book MRQ
1.62
Financials PBYI
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PBYI
For 52 weeks
2.23 USD
5.26 USD
50 Day MA
3.10 USD
Shares Short Prior Month
2 794 988
200 Day MA
3.01 USD
Short Ratio
5.83
Shares Short
2 883 273
Short Percent
6.84 %
BeatStart